诚达药业原始股东或套现6.34亿离场 净利降49%股价较发行价跌超60%

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is experiencing poor performance, leading to continuous share reductions by original shareholders, particularly Shenzhen Qianhai Shengtai Investment Enterprise, which plans to sell up to 11 million shares, potentially cashing out 316 million yuan [1][3][9]. Group 1: Shareholder Actions - Shenzhen Qianhai Shengtai plans to reduce its holdings by up to 11 million shares, representing 7.27% of the company's total shares, within three months starting from September 29, 2025 [2][3]. - Over the past two and a half years, Qianhai Shengtai has reduced its holdings in Chengda Pharmaceutical, cashing out a total of 634 million yuan [1][9]. - The latest reduction plan follows a series of previous reductions, with Qianhai Shengtai having already cashed out 318 million yuan from earlier sales [8][9]. Group 2: Company Performance - For the first half of 2025, Chengda Pharmaceutical reported revenue of 182 million yuan, an increase of 11.24% year-on-year, but net profit fell by 49.06% to 12.82 million yuan [11][12]. - The company's stock price has dropped over 60% from its initial public offering price of 72.69 yuan, with the current price at 28.74 yuan [9][10]. - Chengda Pharmaceutical's revenue and net profit have shown a declining trend over the past few years, with a notable loss of 28.1 million yuan in 2024, marking the first loss since 2010 [12][13]. Group 3: Business Challenges - The decline in revenue is attributed to a 33.22% drop in sales of raw materials, particularly due to clients overstocking in anticipation of national centralized procurement [12][13]. - The CDMO (Contract Development and Manufacturing Organization) segment also faced a 37.65% decline in sales due to increased competition and global economic uncertainties [12][13]. - Chengda Pharmaceutical aims to expand its market presence and enhance its brand value through various promotional activities and by deepening relationships with existing clients [13].